about
Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in SpainProjected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting.IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting.Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States.Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the USSwitching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysisEvaluation of the Long-Term Cost-Effectiveness of Once-Weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in the UKTreating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixiThe management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK settingOnce-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in EstoniaAssessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozinValue For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In ItalyOnce-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the NetherlandsEvaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United StatesEvaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidenceEvaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UKOral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial ProgrammeA Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USAThe Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in SlovakiaThe Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in SpainOral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysisCorrection to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
P50
Q33700904-E39B7948-EE9B-4642-9105-41A8E54E58B4Q37737468-4C94CCBD-85C5-4707-8D3A-3CF3A9FAAB19Q38675810-399AAE01-5C1C-4C44-9BEB-78514A666C6AQ38738725-9273FBD2-E306-4FE7-843F-C196D2BE1087Q38765656-066A8278-2704-496C-8781-2888395ECD50Q42334007-5AEFA0F6-1F31-4B78-84C5-95824B780252Q48221158-B7EBA5D0-EEDC-4A5D-91F4-EB485D1E1B93Q57160154-D3CAC98D-0089-478B-B5C4-9DF3D108B159Q57171961-A3DB5738-63B4-490E-B2EF-D01134E791F6Q58555000-9969E910-A7D5-4774-AE33-BC9CB4D7ED49Q64282576-FF5DC3C4-6A08-4858-8568-149EB12AE7D0Q88803321-365FB9E0-AD5C-4034-A00B-F5163288C9BBQ90395109-66C8E068-9AF3-4BAD-A7C5-759EF8B515B4Q90713324-655F0844-4079-4040-BEBD-86F20818B170Q90835352-06CF3F90-20CC-4691-B676-2AD4DF38D6C5Q90888393-F84EB73C-C554-4BD3-BEC8-ED95032E5F29Q90935294-1431342B-6F8C-492E-A014-71781A2D59E9Q91445223-A83EDFE6-7875-46B7-B4DD-1A10D4A4F36FQ91930591-75F7C12C-FE5F-4E5F-9EB2-559AB9CF4738Q91944631-4296574C-513B-4C9B-B719-EE1659CC4A70Q92386639-848FE9DF-84E2-4E71-BBF4-87875CFD3CEAQ92553180-2888C633-4445-4E21-B5E5-2F3541B8EF2AQ92566996-C4E59BA4-87B2-4DD4-9804-C0A7E517A254Q92991393-67496CE3-547A-4136-B18A-E3A9451C21E8Q93067506-E94A166D-8860-4239-A375-6569718F6555
P50
description
researcher
@en
wetenschapper
@nl
name
Barnaby Hunt
@en
Barnaby Hunt
@nl
type
label
Barnaby Hunt
@en
Barnaby Hunt
@nl
prefLabel
Barnaby Hunt
@en
Barnaby Hunt
@nl
P31
P496
0000-0001-5420-279X